Canada markets closed

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3900+0.2600 (+23.01%)
At close: 04:00PM EST
1.3700 -0.02 (-1.44%)
After hours: 07:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.1300
Bid1.3700 x 1000
Ask1.4700 x 1100
Day's Range1.1300 - 1.5600
52 Week Range0.8600 - 7.3500
Avg. Volume642,876
Market Cap91.848M
Beta (5Y Monthly)2.47
PE Ratio (TTM)N/A
EPS (TTM)-1.9700
Earnings DateFeb 21, 2024 - Feb 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.25
  • GlobeNewswire

    Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

    Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue Strategic reorganization will result in a 40% reduction of workforce Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating ge

  • GlobeNewswire

    Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

    - Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE N

  • GlobeNewswire

    Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

    Figure 1 mRNA expression with T cell ctLNP in humanized mouse model Figure 2 Dose response with T cell ctLNP in humanized mouse model Figure 3a Half-life of stealth LNP in NHPs and mice Figure 3b Biodistribution of stealth LNP in NHPs 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolon